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ence-in-difference method was used to estimate changes in fracture rates two
years before and after ZOL or OBP initiation. Generalized estimating equationmod-
els were used to test the hypothesis of differential changes in fracture rates be-
tween ZOL and OBP users, controlling for age, gender, treatment (ZOL vs. OBP), and
time (pre-period vs. follow-up period). RESULTS: A total of 3,102 ZOL and 36,961
OBP users met the study criteria. Over the two-year follow-up, ZOL users experi-
enced a significant reduction in fracture rates compared to the two-year prior to
ZOL (13.4% vs. 11.2%; p0.008) while fracture rates significantly increased for OBP
users (9.0% vs. 9.5%; p0.019). Multivariate regression estimated that the probabil-
ity of experiencing any fracture decreased by 1.97% between pre- and follow up
period for ZOL users (p0.004), increased by 0.46% for OBP users (p0.001), and the
difference-in-difference effect was 2.43%, suggesting that ZOL users experienced a
significant decrease in fracture rates relative to OBP users (p0.001).
CONCLUSIONS: This is the first comparative analysis evaluating fracture rates two
years before and two years after the initiation of ZOL and OBP. Use of ZOL signifi-
cantly reduced fracture rates, compared with the use of OBP.
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OBJECTIVES: To evaluate costs and clinical response of different treatments with
biologic drugs for rheumatoid arthritis. METHODS: The study was designed as a
prospective cohort. A sample of 15 patients was selected for analysis. Selection
criteria: patients with RA with moderate to severe disease activity, failure to treat-
ment with DMARDS and no previous use of anti-TNF drugs. The following param-
eters were considered in the calculation of direct costs: average doses, treatment
duration, number of doses received and cost per milligram (mg) of each drug. The
clinical outcome evaluated was DAS 28 at day zero and at 160 days. The criteria
considered for low activity of disease was DAS 28 3.2 and for remission DAS 28
2.6. RESULTS: Among the 15 patients included, the average age was 45 years, 33%
were men, with average BMI of 25.81kg/m2, 73% with disease duration above 5
years, and average duration of treatmentwithDMARDs of 2.27 years. Among these,
3 patients were treated with Adalimumab (average dose: 40mg; R$75.13/mg; 6 dos-
es); 3 with Etanercept (average dose: 50mg; R$28.28/mg; 15 doses) and 9 with Inf-
liximab (average dose: 201mg; R$30.77/mg; 4 infusions). The average follow-up
time was 16 weeks. Adalimumab resulted in an average cost of R$18031.41 with a
63% reduction in DAS 28 (2.03), presenting remission criteria. The average cost with
Etanercept was R$21,209.55 with a 3% reduction in DAS 28 (5.31). Infliximab re-
sulted in an average cost of R$ 24,766.11 with a reduction of 26% in DAS 28 (3.23)
presenting criteria for low activity of disease. CONCLUSIONS: The first line treat-
ment of patients withmoderate to severe RAwith Adalimumab presented the best
clinical response in 160 days, achieving criteria for disease remission at the lowest
treatment cost. The treatment with Etanercept resulted in the worst relation be-
tween cost and clinical response.
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OBJECTIVES:Outcomes researchmethodologies need to advance and allow access
by various disciplines as clinicians, epidemiologists, economists, and statisticians
interact frequently. A data visualization tool can help present complex patterns
more effectively to a diverse audience. METHODS: Patients over 65, with at least
one diagnosis for PsA were selected for this study, using the 100% national Medi-
care data with Part D information. We identified patients who initiated therapy
with tumor necrosis factor (TNF) andnon-TNF treatments. For 2 years after biologic
initiation, the following treatment patterns were examined: switching to another
TNF, switching to a non-TNF, and discontinuation.We created a data visualization
tool using a processing language to show how patient treatment patterns change
after the first and second drug switches. RESULTS:A total of 2921 patients initiated
PsA therapy with a TNF agent. 6.44% of these patients switched to another TNF,
2.43% switched to a non-TNF, 51.11% discontinued therapy and 40.02% continued
their initial therapy. Among patients who switched to another TNF, 50.53% re-
mained on the switched therapy, 30.85% discontinued therapy, 18.09% switched to
another TNF, and 0.53% switched to a non-TNF. In 2 years after TNF initiation,
11.76% of patientsmade a second switch from their initial TNF to a third TNFwhile
64.71% continued their second switched drug, 23.53% discontinued the second
switched TNF and no patients switched to a non-TNF. CONCLUSIONS: It can be
difficult to present treatment patterns, especially when analyzing subsequent
years and switches. Data visualization tools can help present these complicated
flows effectively to a diverse health outcomes research audience.
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OBJECTIVES: In recent years, methodologies used in outcomes research have ad-
vanced. In a field where different disciplines interact frequently, a tool to commu-
nicate information clearly and effectively through graphical means has become a
necessity. Using data visualization techniques, we present treatment patterns of
patients diagnosed with rheumatoid arthritis (RA).METHODS: Using the 100% na-
tional Medicare data with Part D information, patients who are over age 65 and
have had 2 diagnoses for RA at least 60 days apart were selected for the study. We
identified patients who initiated therapy with tumor necrosis factor (TNF) agents.
For 2 years after the initiation of TNF, we examined treatment patterns such as
switching to another TNF, switching to a non-TNF, and drug discontinuation. Using
a processing language, we created a data visualization tool to illustrate changes in
treatment patterns after first, second and the third switches. RESULTS: A total of
50,455 RA patients initiated therapywith a TNF. 4.37% of these patients switched to
another TNF, 5.81% switched to a non-TNF, 61.52% discontinued therapy and
28.31% continued their initial therapy. Among patients who switched to another
TNF, 37.36% remained on the switched therapy, 46.71% discontinued, 8.40%
switched to another TNF, and 7.54% switched to a non-TNF. In 2 years after TNF
initiation, 7.03% of patients who switched twice after the initial TNF switched a
third time to another TNF, while 51.35% continued their second switched drug,
35.68% discontinued their second switched TNF, and 5.95% switched to a non-TNF.
CONCLUSIONS: Treatment patterns can be difficult to present, especially if they
were analyzed for subsequent years and switches. Data visualization tools can
assist researchers in the effective presentation of these complicated flows.
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OBJECTIVES: To examine the patterns of depression treatment among individuals
with arthritis and depression by demographic, socioeconomic, access to care,
health status and lifestyle risk factors. METHODS: We used a cross-sectional de-
sign. Our data source was the 2008 annual release of Medical Expenditures Panel
Survey (MEPS). Individuals with self-reported arthritis were identified from medi-
cal conditions andhousehold files. Presence of depressionwas captured frommed-
ical conditions file. The study sample consisted of 947 adults with arthritis and
depression. Unadjusted group differences in depression treatment patterns among
individuals with arthritis and depression were analyzed using Chi-square tests.
Multinomial logistic regressions were used to examine the relationship between
depression treatment and demographic, socioeconomic, access to care, health sta-
tus and lifestyle risk factors. All analysis accounted for complex survey design of
MEPS. RESULTS: Overall, 20% of individuals with arthritis and depression had no
depression treatment, 56%used antidepressants only and 24%used psychotherapy
with or without antidepressants. After controlling for all other independent vari-
ables, we found that compared to whites, African Americans (AOR0.37) and Lati-
nos (AOR0.28) were significantly less likely to use antidepressants only. Individ-
uals with middle income (AOR0.32) were significantly less likely to receive
psychotherapy with or without antidepressants, than individuals with high
income. CONCLUSIONS: One in every five individuals with both arthritis and de-
pression did not have any treatment for depression. Racial and socio-economic
disparities in depression treatment were found. Further research is required to
explore that whether lack of depression treatment results in poor health outcomes
related to arthritis among individuals with arthritis and depression.
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OBJECTIVES: OA is a highly prevalent disease with significant economic implica-
tions. With increased aging and obesity, the incidence and prevalence of OA is
expected to continually rise, resulting in higher utilization of health resources. As
part of a systems dynamicmodelling research programme to inform OA care plan-
ning in Alberta, we used provincial administrative data to estimate OA prevalence
and incidence and examined the sensitivity of estimates to different OA case
definitions.METHODS:WeobtainedAlberta Health andWellness (AHW)Discharge
Abstract (DAD), Physician Claims (Claims) and Ambulatory Care Classification Sys-
tem (ACCS) databases from 1994 to 2010with ICD-9 and ICD-10 OA diagnosis codes
(715 and M15-19 codes) identified in any field. In the base case, OA incidence and
prevalence was captured for patients documented with this diagnosis who had at
least two physician OA visits within two years. RESULTS: The incidence and prev-
alence of OA in 2008were estimated at 7.5 cases/1000 population and 87 cases/1000
population, respectively. OA prevalence wasmost affected by run-in time (number
of years of data), followed by the number of physician visits used to define OA, the
number of years between cases, and the databases applied in the analysis. Over 15
years, prevalence approaches steady-state. Physician Claims data captured most
(98%) of the OA cases.CONCLUSIONS:Administrative data have limitations but are
the only routinely collected population level source for these estimates. The key
factors that impact incidence and prevalence estimates for chronic diseases, like
OA, is the number of years of historical data and number of visits used in the case
definition. These estimates most likely underestimate OA prevalence, but likely
capture clinically relevant disease for which patients seek care. The value of these
data for health authorities is to allow for better prediction of demand for planning
future health services.
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